Low body weight and involuntary weight loss are associated with Raynaud's phenomenon in both men and women by Abdulle, A E et al.
 
 
 University of Groningen
Low body weight and involuntary weight loss are associated with Raynaud's phenomenon in
both men and women
Abdulle, A E; Arends, S; van Goor, H; Brouwer, E; van Roon, A M; Westra, J; Herrick, A L; de
Leeuw, K; Mulder, D J
Published in:
Scandinavian Journal of Rheumatology
DOI:
10.1080/03009742.2020.1780310
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2020
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Abdulle, A. E., Arends, S., van Goor, H., Brouwer, E., van Roon, A. M., Westra, J., Herrick, A. L., de
Leeuw, K., & Mulder, D. J. (2020). Low body weight and involuntary weight loss are associated with
Raynaud's phenomenon in both men and women. Scandinavian Journal of Rheumatology, 1-8.
https://doi.org/10.1080/03009742.2020.1780310
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 26-12-2020
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=irhe20
Scandinavian Journal of Rheumatology
ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/irhe20
Low body weight and involuntary weight loss are
associated with Raynaud’s phenomenon in both
men and women
AE Abdulle , S Arends , H van Goor , E Brouwer , AM van Roon , J Westra , AL
Herrick , K de Leeuw & DJ Mulder
To cite this article: AE Abdulle , S Arends , H van Goor , E Brouwer , AM van Roon , J Westra ,
AL Herrick , K de Leeuw & DJ Mulder (2020): Low body weight and involuntary weight loss are
associated with Raynaud’s phenomenon in both men and women, Scandinavian Journal of
Rheumatology, DOI: 10.1080/03009742.2020.1780310
To link to this article:  https://doi.org/10.1080/03009742.2020.1780310
© 2020 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis
Group.
Published online: 16 Oct 2020.
Submit your article to this journal 
Article views: 103
View related articles 
View Crossmark data
Low body weight and involuntary weight loss are associated with 
Raynaud’s phenomenon in both men and women
AE Abdulle1, S Arends2, H van Goor3, E Brouwer2, AM van Roon1, J Westra2, AL Herrick4, K de Leeuw2, DJ Mulder1
1Department of Internal Medicine, Division Vascular Medicine, University of Groningen, University Medical Center Groningen, 
Groningen, The Netherlands 
2Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, 
The Netherlands 
3Department of Pathology and Medical Biology, Section Pathology, University of Groningen, University Medical Center Groningen, 
Groningen, The Netherlands 
4Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Salford Royal NHS Foundation Trust, 
Manchester Academic Health Science Centre, Manchester, UK
Objectives: Low body weight is an easily assessable cause of Raynaud’s phenomenon (RP), and is frequently overlooked 
by clinicians. We aim to investigate the association of low body weight (body mass index < 18.5 kg/m2), involuntary weight 
loss, and nutritional restrictions with the presence of RP.
Method: Participants from the Lifelines Cohort completed a validated self-administered connective tissue disease 
questionnaire. Subjects who reported cold-sensitive fingers and biphasic or triphasic colour changes were considered 
to suffer from RP. Patient characteristics, anthropometric measurements, and nutritional habits were collected. 
Statistical analyses was stratified for gender.
Results: Altogether, 93 935 participants completed the questionnaire. The prevalence of RP was 4.2% [95% 
confidence interval (CI) 4.1–4.4%], and was three-fold higher in women than in men (5.7% vs 2.1%, p < 0.001). 
Subjects with RP had a significantly lower daily caloric intake than those without RP. Multivariate analysis, correcting 
for creatinine level, daily caloric intake, and other known aetiological factors associated with RP, revealed that low 
body weight [men: odds ratio (OR) 5.55 (95% CI 2.82–10.93); women: 3.14 (2.40–4.10)] and involuntary weight loss 
[men: OR 1.32 (1.17–1.48); women: 1.31 (1.20–1.44)] were significantly associated with the presence of RP. Low-fat 
diet was also associated with RP in women [OR 1.27 (1.15–1.44)].
Conclusion: Low body weight and prior involuntary weight loss are associated with an increased risk of RP in both 
men and women. This study emphasizes that low body weight and weight loss are easily overlooked risk factors for 
RP, and should be assessed and monitored in subjects with RP. 
Raynaud’s phenomenon (RP), which is a common disorder, 
is characterized by an episodic discoloration of the extremi-
ties in response to cold exposure or emotional stress (1, 2). 
Raynaud’s phenomenon is common in young females and 
may be associated with several underlying connective tissue 
diseases (CTDs), including systemic sclerosis. Although 
patients presenting with RP are usually screened for features 
of CTDs, easily measurable causes of RP, such as low body 
weight or recent weight loss, are often overlooked.
In clinical practice, many patients with RP are under-
weight, have recently lost weight, or have dietary 
restrictions, potentially leading to malnutrition. Several 
case reports have demonstrated that RP can concomitantly 
occur in certain eating disorders (3, 4). In addition, it was 
reported that patients with anorexia nervosa suffering from 
RP exhibit nailfold capillaroscopic findings typical of 
a CTD (5). Collectively, these findings suggest that low 
body weight increases a patient’s susceptibility to RP. 
However, studies investigating the relationship between 
low body weight, weight loss, and RP are lacking.
The objective of the current study is to investigate the 
association of low body weight, involuntary weight loss, 
and dietary restrictions with the presence of RP in the 
general population. In addition, we will investigate other 
factors that are associated with low body weight, including 
diets based on low-fat and low-carbohydrate intake. To gain 
a clear understanding on the relationship between low body 
weight and RP, we will adjust for factors associated with 
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low body weight [i.e. creatinine level (as a surrogate of 
muscle mass) and daily caloric intake] and other known 
aetiological factors associated with RP [i.e. age, hormonal 




In this cross-sectional study, we analysed data from the 
Lifelines Cohort Study. Lifelines is a prospective, multi-
disciplinary population-based cohort study, examining the 
health and health-related behaviours of 167 729 people from 
three generations, living in the north of the Netherlands (6). 
Inclusion of the participants started in 2013, and all partici-
pants will be followed for 30 years. Prior to the first visit at 
the Lifelines outpatient clinic, all participants were asked to 
complete a self-administered questionnaire, and to provide 
(self-reported) information about their medical history, cur-
rent diseases, use of medication, and health behaviour. 
During the first visit all participants underwent a general 
clinical examination, followed by blood and urine collec-
tion. All participants were aged ≥ 18 years, and subjects 
were only excluded from the current study if the CTD 
screening questionnaire (for details, see below) was miss-
ing. The Lifelines Cohort Study was conducted according to 
the principles of the Declaration of Helsinki and approved 
by the local medical ethics review committee of the Uni-
versity Medical Centre Groningen (UMCG), and all parti-
cipants provided written informed consent to participate in 
this study.
Data collection
The Lifelines Cohort is a comprehensive source of demo-
graphic, physical, biomedical, behavioural, and psychologi-
cal data. Information on the data access procedure can be 
found at http://www.Lifelines.nl. For the current study, 
several baseline patient characteristics were obtained, e.g. 
gender, age, smoking behaviour (current smoking was 
defined as smoking at the time of study entry or in the past 
month), hormonal status (i.e. pre vs post-menopausal, 
receiving hormonal contraceptives, receiving hormonal 
treatment other than contraceptives), and medication use 
(beta-blocking agents, immunosuppressive drugs, and cen-
tral-acting sympathomimetics).
CTD screening questionnaire
Lifelines participants completed a number of question-
naires, including a CTD screening questionnaire, during 
the follow-up assessment, which took place within 3 years 
of the baseline assessment [median 25 months, interquartile 
range (IQR) 23–31 months]. This validated questionnaire 
comprised 30 questions designed to identify potential 
CTDs, including the presence of RP (7, 8). The two-panel 
methodology was applied to translate the English CTD 
questionnaire. A bilingual panel agreed on the best Dutch 
translations for the items. Subsequently, the questionnaire 
was presented to a lay panel for consideration. This panel 
consisted of both men and women of different ages and 
average level of education (non-medical) to ensure that the 
language being used in the final version would be under-
stood by potential respondents, and that it was in everyday 
Dutch. The presence of RP was assessed using five specific 
questions of the CTD questionnaire, namely: ‘Are your 
fingers unusually sensitive to the cold?’(question 1), ‘Have 
your fingers ever shown any unusual colour changes in the 
cold?’ (question 2), ‘If your fingers have ever shown any 
unusual colour changes in the cold, was the colour white?’ 
(question 3), ‘If your fingers have ever shown any unusual 
colour changes in the cold, was the colour blue/purple?’ 
(question 4), and ‘If your fingers have ever shown any 
unusual colour changes in the cold, was the colour red?’ 
(question 5). Subjects who answered the first two questions 
(questions 1 and 2) with a ‘yes’ were considered to possibly 
be suffering from RP, and participants who answered both 
questions with a ‘yes’ and reported biphasic or triphasic 
discoloration of the fingers were classified as definite RP 
(9). In addition, subjects who answered the first two ques-
tions with a ‘no’ were considered as non-RP participants.
Dietary assessment
To assess factors associated with low body weight, a 110- 
item food frequency questionnaire was used. This question-
naire was designed to assess food intake over the previous 
month (10). In addition, daily energy and macronutrient 
intake [daily caloric intake (kcal), daily intake of carbohy-
drates (g/day), and daily intake of fat (g/day)] was calculated 
based on the answers provided on the food frequency ques-
tionnaire at baseline. A low-fat diet was defined as a diet in 
which < 30% of the total calories were derived from fat (11, 
12), a low-carbohydrate diet was defined as a diet in which 
< 26% of the total calories were derived from carbohydrates 
(13), and low-calorie intake was defined as < 1000 kcal/day. 
Serum creatinine was measured on a Roche Modular 
P chemistry analyser (Roche, Basel, Switzerland) and was 
used as a surrogate measure of muscle mass, as previously 
demonstrated (14, 15). Other weight-loss specific questions 
included are: ‘What was your lowest weight in the last 
5 years?’, ‘Are you currently on a diet to lose weight?’, 
and ‘Have you ever experienced involuntary weight loss 
(6 kg in 6 months, or 3 kg in 1 month)?’
Physical assessments
At baseline, participants were invited to visit one of 12 
Lifelines research sites to undergo a physical examination 
and a series of tests. Anthropometric measurements 
including height (cm), weight (kg), and body mass index 
(BMI) were conducted by nurses during the study visit. 
BMI was categorized into two groups (BMI < 18.5 kg/m2 
and BMI ≥ 18.5 kg/m2).
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Statistical analysis
Statistical analysis was performed with SPSS version 
22 (released 2013; IBM Corp., Armonk, NY, USA). 
Results were expressed as numbers of subjects (per-
centages) mean ± sd, or median [interquartile range 
(IQR)] for categorical, normally, and non-normally 
distributed data, respectively. The chi-squared test, 
independent samples t-test, and Mann-Whitney U- 
test were used as appropriate to compare characteris-
tics between participants with and those without RP. 
Binary logistic regression with the presence of defi-
nite RP (no/yes) as the dependent variable was per-
formed [presented as odds ratio (OR) and 95% 
confidence interval (CI)] to assess the association 
between BMI, weight loss, and the presence of RP. 
Since BMI and weight loss can cause problems of 
collinearity if included together, these variables were 
included separately in the model. Variables that were 
statistically significant in the univariate analyses were 
further analysed in multivariate logistic regression 
(enter method) to correct for potential confounders 
[creatinine level (as a surrogate measure of muscle 
mass), daily caloric intake, age, known CTD, smok-
ing, and use of medications (beta-blocking agents, 
immunosuppressive drugs, and central-acting sym-
pathomimetics)]. In women, we additionally corrected 
for hormonal status (pre- vs post-menopausal, receiv-
ing hormonal contraception, receiving hormonal treat-
ment other than contraception). Current literature has 
shown that BMI and weight loss may be influenced 
by daily caloric intake and muscle mass (creatinine 
was used as a surrogate of muscle mass) and there-
fore we decided to correct for these parameters (16, 
17, 18, 19). We also corrected for other known aetio-
logical factors associated with RP, such as age, 
known CTD, hormonal status, smoking, and use of 
medication (i.e. beta-blocking agents, immunosup-
pressive drugs, and central-acting sympathomimetics). 
All analyses were stratified for gender (effect modi-




In total, 152 020 participants were included in the Life-
lines Cohort Study. The CTD questionnaire was com-
pleted by 93 935 (61.8% of total) (Figure 1), with 
a mean age of 45.6 ± 12.9 years, of whom 56 122 
(59.7%) were women and 37 813 (40.3%) men. Further 
characteristics of the responders can be found in Table 
1. Of the non-responders (participants who were sent 
the questionnaire but declined to complete, total 
n = 58 085), 32 901 (56.5%) were women and the 
mean age was 43.1 ± 13.4 years.
Prevalence of RP
Figure 2 shows the prevalence of RP in our cohort. In 
total, 3927 participants reported at least biphasic disco-
loration, and thus were classified as definite RP. The 
overall prevalence rate of definite RP was found to be 
4.2% (95% CI 4.1–4.4). Regarding the age-specific 
prevalence rates, we observed that the prevalence of 
definite RP decreases with increasing age. Participants 
aged 18–20 years showed the highest prevalence rate 
[men 2.5% (95% CI 1.3–4.7%), women 10.2% (8.5–-
12.3%), p < 0.001], and prevalence was found to 
decline with age.
Differences in anthropometric measurements and 
dietary assessment in participants with and without RP
Subjects with RP had a lower current weight than sub-
jects without RP (p < 0.001). In addition, low body 
weight (BMI < 18.5 kg/m2) was more frequently 
found in subjects with RP than in those without RP 
(RP 2.3%, non-RP 0.5%, p < 0.001). The lowest (self- 
measured) weight reported in the last 5 years was 8 kg 
lower in subjects with RP than in subjects without RP 
[RP median 65 kg (IQR 58–73 kg), non-RP 73 kg 
(64–83 kg), p < 0.001). In addition, subjects with RP 
more frequently reported having suffered from involun-
tary weight loss (RP 5.3%, non-RP 2.6%, p < 0.001). 
With regard to nutritional information, subjects with RP 
had a significantly lower daily caloric intake than sub-
jects without RP (RP 1798 kcal/day, non-RP 1911 kcal/ 
day, p < 0.001). However, the number of subjects who 
were currently on a diet to lose weight did not differ 
between groups (p = 0.645). Creatinine levels, as a sur-
rogate of muscle mass, were also found to be signifi-
cantly lower in subjects with RP [RP median 70 µmol/L 
(IQR 63–77 µmol/L), non-RP 73 µmol/L (65–82 µmol/ 
L), p < 0.001).
Association between BMI and RP
The interaction term between BMI and gender was 
found to be statistically significant (p = 0.01), which 
indicates that gender is an effect modifier. Therefore, 
the univariate and multivariate analyses were stratified 
for gender and are presented in Figure 3A and B, 
respectively.
In men, the univariate analysis showed that weight 
(kg), low body weight (BMI < 18.5 kg/m2), and invo-
luntary weight loss were significantly associated with 
the presence of RP. The multivariate analyses revealed 
that, after correction for potential confounders, these 
variables remained significantly associated with the pre-
sence of RP (Figure 3B) [weight OR 0.96 (95% CI 
0.96–0.97), low body weight OR 5.55 (2.82–10.93), 
involuntary weight loss OR 1.32 (1.17–1.48)].
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Figure 1. Overview of the reported discoloration of the hands. A total of 93 935 subjects completed the questionnaire, of whom 10.6% reported 
monophasic discoloration. Of the subjects who reported monophasic discoloration, 4.2% also reported biphasic or triphasic discoloration. CTD, 
connective tissue disease.
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In women, the univariate analyses showed that 
weight (kg), low body weight, involuntary weight 
loss, low-carbohydrate diet, and low-fat diet were 
significantly associated with the presence of RP. 
After adjustment for potential confounders, these 
variables, with the exception of low-carbohydrate 
diet, remained significantly associated with the pre-
sence of RP [weight OR 0.97 (95% CI 0.96–0.97), 
low body weight OR 3.14 (2.40–4.10), involuntary 
weight loss OR 1.31 (1.20–1.44), and low-fat diet 
OR 1.27 (1.15–1.41)].
Discussion
To the best of our knowledge, this is largest study to 
investigate the association between low body weight, 
involuntary weight loss, dietary restriction, and RP in the 
general population. We clearly demonstrated that low 
body weight and prior involuntary weight loss are signifi-
cantly associated with an increased risk of RP in both men 
and women. In addition, low-fat diet was found to be 
associated with RP in women, but not in men. These 
associations remained present after correction for known 
aetiological factors associated with RP and other factors 
that might influence body weight. Conversely, low-calorie 
intake (< 1000 kcal/day) was not found to be associated 
with RP. Collectively, our results underline the impor-
tance of body weight and nutritional issues as easily over-
looked associates of RP.
Subjects with RP had a lower daily caloric intake 
(approximately 100 kcal lower) than those without RP. 
The number of subjects who were currently on a diet to 
lose weight did not differ between groups. In addition, 
we demonstrated that underweight subjects and subjects 
with involuntary weight loss had an increased odds of 
Table 1. Patient characteristics of the total group, and participants with and without Raynaud’s phenomenon (RP).
Patient characteristics
Total responders 
(n = 93 935)
Non-RP 
(n = 70 037)
RP 
(n = 3927) p*
Gender, female 56 122 (59.7) 39 185 (55.9) 3154 (80) < 0.001
Age at baseline (years) 46 (37–54) 45 (37–53) 43 (33–50) < 0.001
Comorbidities
CTD (SLE, Sjögren, systemic sclerosis) 40 (0.04) 4 (0.006) 4 (0.1) 0.61
Use of medication
Beta-blockers 5408 (5.8) 3674 (5.2) 222 (5.7) 0.27
Immunosuppressive drugs 2578 (2.7) 1698 (2.4) 166 (4.2) < 0.001
Central-acting sympathomimetic 317 (0.3) 200 (0.3) 25 (0.6) < 0.001
Smoking behaviour
Current smoker 17 507 (18.6) 12 952 (18.5) 749 (19.1) 0.65
Anthropometric measurements
Weight (kg) 78 (69–89) 79 (70–90) 70 (63–80) < 0.001
Length (cm) 174 (168–182) 175 (168–182) 172 (167–178) < 0.001
BMI (kg/m2) 25.4 (23.1–28.1) 25.6 (23.4–28.4) 23.5 (21.4–26.1) < 0.001
Low body weight (BMI < 18.5 kg/m2) 697 (0.8) 372 (0.5) 92 (2.3) < 0.001
Nutritional information
On a diet to lose weight 5969 (6.4) 4425 (6.3) 241 (6.1) 0.645
Lowest weight in the last 5 years 72 (63–82) 73 (64–83) 65 (58–73) < 0.001
Involuntary weight loss  
(6 kg in 6 months or 3 kg in 1 month)
2780 (3.0) 1805 (2.6) 207 (5.3) < 0.001
Daily caloric intake (kcal) 1888 (1484–2319) 1911 (1501–2341) 1798 (1431–2233) < 0.001
Low-calorie intake (< 1000 kcal/day) 8645 (9.2) 8192 (11.7) 453 (11.5) 0.76
Daily intake of carbohydrates (g/day) 210 (163–2320) 213 (164–264) 206 (160–256) < 0.001
Low-carbohydrate diet 3368 (3.6) 2528 (3.6) 126 (3.2) 0.19
Daily intake of fat (g/day) 73 (54–94) 74 (55–94) 69 (51–89) < 0.001
Low-fat diet 17 355 (18.5) 12 934 (18.5) 810 (20.6) 0.001
Creatinine level (µmol/L) 72 (64–81) 73 (65–82) 70 (63–77) < 0.001
Data are shown as n (%) or median (interquartile range). 
CTD, connective tissue disease; SLE, systemic lupus erythematosus; BMI, body mass index. 























Figure 2. Prevalence (95% confidence intervals) of Raynaud’s phe-
nomenon (RP), in the different age groups, shown for men and 
women.
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RP, independently of age, current smoking, creatinine 
level (as a surrogate measure of muscle mass), daily 
caloric intake, and hormonal status (in women). How-
ever, studies focusing on the relationship between BMI 
and RP are very limited, and, therefore, the exact causal 
relationship remains poorly understood. For instance, it 
could hypothesized that substantial weight loss (or 
a BMI < 18.5 kg/m2) increases a person’s susceptibility 
to RP. A possible explanation is that weight loss may 
lead to a loss of subcutaneous and perivascular adipose 
tissue, and subsequently increases the susceptibility to 
vasospastic events. In support of this, it has been shown 
that perivascular adipose tissue alters the balance 
between endothelium-dependent vasodilator and vaso-
constrictor substances (e.g. nitric oxide and endothelin- 
1) (20), which further underlines the importance of BMI 
(and more importantly recent weight loss) in the occur-
rence of RP. In addition, a previous study showed that 
low body weight was also associated with an increased 
risk of cardiovascular disease (CVD) (21). The authors 
stated that the increased risk of CVD could potentially 
be explained by the poor nutritional status and the 
decline in muscle mass in underweight subjects (21). 
Furthermore, it was previously reported that subjects 
with low muscle mass were at increased mortality risk 
(22). Although only a surrogate marker of muscle mass, 
the current study found that subjects with RP had lower 
levels of creatinine. Therefore, it could be hypothesized 
that subjects with low muscle mass may also have 
a higher susceptibility to developing RP. Collectively, 
Low-calorie intake (<1000)
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Figure 3. (A) Univariate and (B) multivariate analysis of the relationship between the presence of Raynaud’s phenomenon and low body weight, 
involuntary weight loss, body weight (kg), low-carbohydrate diet, low-fat diet, and low-calorie intake, shown for men and women. In the multivariate 
analysis we corrected for creatinine level (as a surrogate measure of muscle mass), daily caloric intake, age, known connective tissue disease., smoking, 
and use of medication (i.e. beta-blocking agents, immunosuppressive drugs, and central-acting sympathomimetics). In women, we additionally corrected 
for hormonal status (pre- vs post-menopausal, receiving hormonal contraception, receiving hormonal treatment other than contraception).
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these results underline the importance of investigating 
body composition to differentiate the separate contribu-
tions of muscle and fat mass as possible contributory 
factors for RP. Given that an increase in body weight 
was found to be associated with a slightly decreased 
odds of RP, future studies should also focus on the 
potentially protective effects of fat.
In our study, the association of low body weight and 
involuntary weight loss with the presence of RP 
remained present after correction for hormonal status 
(including hormonal treatment other than contraceptives) 
in women. This indicates that the causal pathway in 
which BMI affects RP is not solely mediated by hormo-
nal factors in women, and that other unknown factors 
may have a greater role in this pathway. We found that 
a low-fat diet was associated with an increased risk of RP 
in women. This could indicate a poor nutritional status 
(23). However, studies investigating dietary restrictions 
in RP do not exist and, therefore, the clinical relevance of 
this association is merely speculative.
This is the largest epidemiological study to assess the 
prevalence of RP in the general population. Garner et al 
conducted a meta-analysis and reported an overall preva-
lence of definite RP ranging between 1.6% and 7.2% (24). 
This is in accordance with our findings; however, other 
studies have reported much lower and also higher preva-
lence rates (25, 26). The large variation in prevalence rates 
could be explained by regional differences, as previous 
studies have clearly demonstrated that the prevalence of 
RP is increased in colder regions of the world (27). In 
support of this, Fraenkel et al and Brand et al reported 
prevalences of 7.8% and 7.2%, respectively, in Boston 
(USA) (1, 28). In countries with a warmer climate, the 
prevalence of RP was estimated to range between 2% and 
6% (29, 30, 31). The variation in reported prevalence rates 
can also be explained by differences in the definition of RP. 
For instance, only 39% of the previously conducted studies 
investigating the prevalence of RP used a precise definition 
of RP (24). Without a universally agreed upon definition, 
studies may overestimate or underestimate the true preva-
lence of RP (32, 33). The definition used in the current study 
was comparable to several previously conducted studies 
(26, 33, 34), and is in accordance with the definition used 
by the UK Scleroderma Study Group (9).
The limitations of this study include the cross- 
sectional design, which does not allow the investigation 
of causality. In addition, the primary outcome para-
meters were solely based on questionnaires, which 
could have introduced bias into our paper. However, 
this is a population-based study, which was designed to 
answer multiple research questions, and was not set up 
only for the purpose of the current paper. Since a large 
sample of the general population of the northern parts of 
the Netherlands was included, the clinical information 
that could feasibly be assessed in such a large sample 
was limited. In line with this limitation, more specific 
assessment of CTD-specific data (including nailfold 
videocapillaroscopy) was not feasible at that point. 
Therefore, other approaches for the diagnosis of RP, 
as previously suggested by others, were not deemed 
possible (33, 35, 36, 37) Furthermore, the self-reported 
nature of the CTD questionnaire might lead to an over-
estimation of the prevalence of RP. However, the CTD 
questionnaire used in the current study had been pre-
viously validated, and was found to have a high sensi-
tivity and specificity for screening large populations (7). 
Furthermore, the CTD questionnaire was completed 
within 3 years following the baseline assessment. 
Although variables assessed at baseline (e.g. body 
weight) could have changed over time, we believe that 
given the large sample size of this study this would only 
minimally influence our results. In addition, occupa-
tional exposure was not included in the current study. 
Therefore, the role of environmental factors (e.g. use of 
vibrating tools) remains unknown. Nevertheless, our 
study provides crucial information on the true burden 
of RP in the general population and its relationship with 
low body weight. Our study should raise awareness 
among physicians to pay more attention to body weight 
and nutritional issues as possible treatable causes of RP.
Conclusion
This large population-based cohort study clearly 
demonstrated that low body weight and prior involun-
tary weight loss are significantly associated with an 
increased risk of RP in both men and women. The 
current study underlines the importance of these possi-
bly treatable associates of RP, and further emphasizes 
that BMI and weight changes should be carefully 
assessed and monitored in subjects presenting with RP.
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